Syndax Pharmaceuticals (SNDX) Change in Account Payables (2015 - 2026)

Syndax Pharmaceuticals' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$5.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 263.33% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at $796000.0 (down 35.7% YoY), while the FY2025 annual figure was $5.0 million, up 197.54% from the prior year.
• Change in Account Payables was -$5.7 million for Q1 2026 at Syndax Pharmaceuticals, down from $2.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $7.3 million in Q2 2025 to a low of -$6.7 million in Q3 2024.
• Historically, Change in Account Payables has averaged $304352.9 across 5 years, with a median of $676000.0 in 2022.
• Biggest YoY gain for Change in Account Payables was 262.97% in 2023; the steepest drop was 829.29% in 2023.
• A 5-year view of Change in Account Payables shows it stood at -$2.8 million in 2022, then surged by 241.53% to $3.9 million in 2023, then soared by 71.98% to $6.7 million in 2024, then slumped by 59.07% to $2.8 million in 2025, then sank by 308.32% to -$5.7 million in 2026.
• The last three Change in Account Payables figures came in at -$5.7 million (Q1 2026), $2.8 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.